Impel Pharmaceuticals downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded Impel Pharmaceuticals to Hold from Buy without a price target. Impel’s quarterly filing reaffirms substantial doubt about the company’s ability to continue as a going concern, the analyst tells investors in a research note. While Trudhesa script demand continued to improve, there are “limited reasons for optimism” given the risk of default and lack of clarity on the company’s potential path to sustainability, says the firm.